Clinical trial · Observational
Optimal Surgical Approach for Early-Stage Breast Cancer in Chinese Patients Aged ≤ 40 Years: a Cohort Study
NCT06603805CI-TRIAL-00080544completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The optimal surgical treatment option (BCS+RT versus MAST) for young patients with early-stage breast cancer remains debated. The present study aims to explore trends in surgical management and compare survival outcomes between BCS+RT and MAST in young patients with early-stage breast cancer, ultimately providing optimal treatment strategies for Asian populations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| breast-conserving surgery plus adjuvant radiotherapy | Procedure | — | UNRESOLVED |
| MAST group | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MAST group
- description
- patients 1) aged between 18-40 years; 2) with a primary pathological diagnosis of invasive breast cancer; 3) receiving MAST; 4) having detailed information on T stage, N stage, clinical stage, hormone receptor status, endocrine therapy, and targeted therapy.
- interventionNames
- Procedure: MAST group
- label
- BCS+RT group
- description
- Patients 1) aged between 18-40 years; 2) with a primary pathological diagnosis of invasive breast cancer; 3) receiving BCS+ RT; 4) having detailed information on T stage, N stage, clinical stage, hormone receptor status, endocrine therapy, and targeted therapy.
- interventionNames
- Procedure: breast-conserving surgery plus adjuvant radiotherapy
Primary outcomes (4)
- measure
- Breast cancer-specific survival (BCSS)
- timeFrame
- Jan 1, 2008 to 31 Dec, 2019
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18-40 years. * Pathological diagnosis of invasive breast cancer. * Undergoing Breast-Conserving Surgery (BCS) with Radiotherapy (RT) or Mastectomy (MAST). * Availability of detailed clinical information, including: Tumor (T) stage. Node (N) stage. Clinical stage. Hormone receptor status. Endocrine therapy details. Targeted therapy details. Exclusion Criteria: * Male patients. * Patients with distant metastatic disease. * Patients with bilateral breast cancer. * Patients not undergoing surgery. * Follow-up time of less than 1 month.
References
Publications (0)
Data not yet available
No reference posted for this study.